Antibody conjugates: from heterogeneous populations to defined reagents
OPEN ACCESS
Loading...
Author / Producer
Date
2015-09
Publication Type
Review Article
ETH Bibliography
yes
Citations
Altmetric
OPEN ACCESS
Data
Rights / License
Abstract
Monoclonal antibodies (mAbs) and their derivatives are currently the fastest growing class of therapeutics. Even if naked antibodies have proven their value as successful biopharmaceuticals, they suffer from some limitations. To overcome suboptimal therapeutic efficacy, immunoglobulins are conjugated with toxic payloads to form antibody drug conjugates (ADCs) and with chelating systems bearing therapeutic radioisotopes to form radioimmunoconjugates (RICs). Besides their therapeutic applications, antibody conjugates are also extensively used for many in vitro assays. A broad variety of methods to functionalize antibodies with various payloads are currently available. The decision as to which conjugation method to use strongly depends on the final purpose of the antibody conjugate. Classical conjugation via amino acid residues is still the most common method to produce antibody conjugates and is suitable for most in vitro applications. In recent years, however, it has become evident that antibody conjugates, which are generated via site-specific conjugation techniques, possess distinct advantages with regard to in vivo properties. Here, we give a comprehensive overview on existing and emerging strategies for the production of covalent and non-covalent antibody conjugates.
Permanent link
Publication status
published
External links
Editor
Book title
Journal / series
Volume
4 (3)
Pages / Article No.
197 - 224
Publisher
MDPI
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Immunoglobulin; Bioconjugation; Antibody conjugates; Chemical conjugation; Enzymatic conjugation; Non-covalent antibody conjugates
Organisational unit
02020 - Dep. Chemie und Angewandte Biowiss. / Dep. of Chemistry and Applied Biosc.